Ocular Therapeutix Touts Landmark Phase 3 AXPAXLI Win at RBC Ophthalmology Conference [Yahoo! Finance]
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: Yahoo! Finance
plans to file for FDA approval based on SOL-1 alone , while the second Phase 3 trial SOLAR is ongoing with a readout expected in Q1 next year. Management says the reported "floaters" were likely drug particles seen peripherally with no impact on vision, that a data safety monitoring committee has observed "no issues," and the company does not expect safety concerns to affect SOLAR. Executives contend SOL-1 enrolled highly anti-VEGF–dependent, high-vision patients—making vision-gain comparisons inappropriate—and believe AXPAXLI could perform better in routine practice and be rapidly adopted, particularly for patients seeking fewer injections. Interested in Ocular Therapeutix, Inc.? Here are five stocks we like better. Ocular Therapeutix (NASDAQ:OCUL) executives highlighted what the company described as a landmark Phase 3 outcome for its retinal disease candidate AXPAXLI and discussed ongoing development, safety questions, and regulatory strategy during RBC Capital Markets' Opht
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug [Yahoo! Finance Canada]Yahoo! Finance Canada
- EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug [Yahoo! Finance]Yahoo! Finance
- What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down [Yahoo! Finance]Yahoo! Finance
- Is It Time To Reassess Ocular Therapeutix (OCUL) After Its Recent Share Price Slide [Yahoo! Finance]Yahoo! Finance
- 3 Reasons to Avoid OCUL and 1 Stock to Buy Instead [Yahoo! Finance]Yahoo! Finance
OCUL
Earnings
- 11/4/25 - Beat
OCUL
Sec Filings
- 2/27/26 - Form 8-K
- 2/25/26 - Form 4
- 2/25/26 - Form 4
- OCUL's page on the SEC website